Division of Cardiovascular Medicine, Oregon Health & Science University, Portland, Oregon 97239, USA.
JACC Cardiovasc Imaging. 2010 Feb;3(2):204-11. doi: 10.1016/j.jcmg.2009.09.021.
Methods for noninvasive imaging of specific disease-related molecular changes are being developed in order to expand and improve diagnostic capabilities and to enhance therapeutic decision making in the clinical setting. These new techniques have also started to be incorporated into research programs in order to better characterize pathophysiology or evaluate treatment efficacy. Molecular imaging with contrast-enhanced ultrasound relies on the detection of the acoustic signal produced by either microbubbles or other acoustically active particulate agents that are targeted to sites of disease. This review describes the progress that has been made in the development and testing of methods for contrast ultrasound molecular imaging of cardiovascular disease. Specifically, topics that will be addressed include: 1) the bioengineering and detection schemes for targeted probes; 2) specific disease processes (myocardial ischemia, atherosclerosis, and transplant rejection) where molecular imaging may play a role; and 3) the potential role of ultrasound as a molecular imaging technique.
为了扩展和提高临床诊断能力，并增强治疗决策，正在开发用于非侵入性成像特定疾病相关分子变化的方法。这些新技术也已开始纳入研究计划，以便更好地描述病理生理学或评估治疗效果。对比增强超声的分子成像是依赖于检测由微泡或其他靶向疾病部位的声活性颗粒剂产生的声学信号。本综述描述了在开发和测试心血管疾病对比超声分子成像方法方面取得的进展。具体而言，将涉及以下主题：1）靶向探针的生物工程和检测方案；2）分子成像可能发挥作用的特定疾病过程（心肌缺血、动脉粥样硬化和移植排斥）；3）超声作为分子成像技术的潜在作用。
